No information is available on the clinical use of afatinib during breastfeeding. Because afatinib is about 95% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 37 hours and it might accumulate in the infant. the manufacturer recommends that breastfeeding be discontinued during afatinib therapy and for 2 weeks after the last dose.
关于阿法替尼在母乳喂养期间的临床应用尚无可用信息。由于阿法替尼约95%与血浆蛋白结合，乳汁中的含量可能较低。然而，其半衰期约为37小时，可能会在婴儿体内蓄积。制造商建议在阿法替尼治疗期间及最后一剂后2周内停止母乳喂养。
